Yervoy

DRUG5 trials

Sponsors

H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb, HonorHealth Research Institute, Shanghai Henlius Biotech

Conditions

Hepatocellular Carcinoma (HCC)MelanomaRenal Cell CarcinomaUveal Melanoma

Phase 1

Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma

CompletedNCT01496807

H. Lee Moffitt Cancer Center and Research InstituteMelanoma

Start: 2012-02-17End: 2016-08-29Updated: 2017-04-28

Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma

CompletedNCT05004025

HonorHealth Research InstituteUveal Melanoma

Start: 2022-02-28End: 2025-07-23Updated: 2025-08-15

Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

RecruitingNCT07176650

Shanghai Henlius BiotechHepatocellular Carcinoma (HCC)

Start: 2025-11-25End: 2026-12-01Target: 246Updated: 2026-03-16

Phase 2

An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma

CompletedNCT03029780

Bristol-Myers SquibbRenal Cell Carcinoma

Start: 2017-02-16End: 2021-06-15Updated: 2022-06-29

Unknown Phase

Yervoy Pregnancy Surveillance Study

WithdrawnNCT02854488

Bristol-Myers SquibbMelanoma

Start: 2016-09-30End: 2021-03-05Updated: 2022-03-31

Related Papers

Administration of nivolumab plus ipilimumab: Infusion of the fixed‐ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800)

Cancer2025-07-04

Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial

BMJ Open2022-09-015 citations

A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma

Journal for ImmunoTherapy of Cancer2016-11-2125 citations

A phase IB study of ipilimumab with peginterferon alfa-2b for patients with unresectable stages IIIB/C/IV melanoma.

Journal of Clinical Oncology2014-05-2011 citations